期刊文献+

联合降阶梯方案治疗婴幼儿喘息疗效及安全性研究 被引量:27

A study on efficacy and safety of combine-counter gradient therapy for infants wheezing
原文传递
导出
摘要 目的探讨联合降阶梯方案治疗婴幼儿喘息的疗效和安全性。方法以2010年10至12月于上海交通大学医学院附属新华医院哮喘专科门诊及普通儿科呼吸门诊就诊的婴幼儿喘息患儿97例作为研究对象,以规范采用联合降阶梯疗法患儿作为治疗组,以仅采用门诊常规治疗的患儿作为对照组(非联合降阶梯疗法组)。两组均采用相同综合性治疗,包括吸氧、退热等对症处理。治疗组口服泼尼松5mg/d,每天1次,疗程3d;口服阿奇霉素0.1g(/kg·d),疗程3d;每晚用妥洛特罗贴剂1贴(0.5mg/d),疗程7d;口服氯雷他定3mL/d,疗程14d;口服孟鲁司特钠4mg/d,疗程21d。对照组采用目前门诊常用治疗方案,包括采用静脉滴注琥珀氢考或甲强龙、平喘药物、抗生素、祛痰止咳合剂、雾化吸入激素等。结果治疗组患儿咳嗽、喘息、哮鸣音评分及症状体征消失天数显著低于对照组(P<0.05),治疗组1个月内复发次数、治疗费用、家长误工天数显著低于对照组(P<0.05),且治疗组患儿对该方案接受度较高(P<0.05)。结论联合降阶梯疗法应用于婴幼儿喘息疗效肯定,且方便、安全,值得临床应用推广。 Objective To evaluate the efficacy and safety of combine-counter gradient therapy for infants wheezing.M ethods Totally 97 patients from Asthma and General Clinic form October to December 2010,who received combine-counter gradient therapy were chosen as test group,patients with general treatment as control group.The two groupsa dopted same synthetic therapy,such as oxygen therapy or pyretolysis.The treatment protocol for test group was oralp rednisone 5mg/d,3 days;azithromycin 0.1g/(kg·d),3 days;tulobuterol patch(0.5mg/d),7 days;loratadine 3ml/d,14d ays;montelukast 4mg/d,21 days.Control group had antibiotics(primarily cephamycin or azithromycin)intravenous injection,methylprednisolone,expectorants and inhale corticoids by atomization.Results Scores of cough,gasping,w heezing rale,recurrence within 1 Month,and charge of therapy and absenteeism rate of parents of test group were significantly lower than contol group(P0.05).Moreover,treatment protocols of test group were prone to be more easilya ccepted(P0.05).Conclusion Combine-counter gradient therapy for infants wheezing is effective,convenient ands afe,which deserves clinical application.
出处 《中国实用儿科杂志》 CSCD 北大核心 2012年第3期202-205,共4页 Chinese Journal of Practical Pediatrics
基金 上海市科委生物医学重点基金资助项目(08411953200)
关键词 联合方案 降阶梯 婴幼儿 喘息 吸氧 退热 combine gradient counter gradient infants wheezing oxygen pyretolysis
  • 相关文献

参考文献13

  • 1中华医学会儿科学分会呼吸学组.儿童支气管哮喘防治常规(试行)[J].中华儿科杂志,2004,42(2):100-106. 被引量:2630
  • 2Piedimote G. Pathophoysiological mechanisms for the respiratory syncytial virus-reactive airway disease link [J]. Respir Res, 2002,3 (S1) :21-25.
  • 3Castro-Rodriguez JA, Holberg C J, Wright AL, et al. A clinical index to define risk of asthma in young children with recurrent wheezing [J]. Am J Respir Crit Care Med, 2000, 162: 1403-1407.
  • 4Yoshihara S, Fukuda H, Abe T, et al. Comparative study of skin permeation profiles between brand and genetic tulobuterol patches[J]. Biol Pharm Bull, 2010,33(10) : 1763-1765.
  • 5黄昀.白三烯受体拮抗剂对5岁以下哮喘患儿预后影响研究[J].中国全科医学,2010,13(24):2685-2687. 被引量:9
  • 6Amlani S, Mclvor RA. Montelukast in childhood asthma: what is the evidence for its use? [J].Expert Rev Respir Med, 2011,5 (1):17-25.
  • 7钱耀琴,顾洪亮,张少明,王平,胡建芬.氯雷他定对哮喘儿童P-选择素表达的抑制作用及临床意义[J].临床儿科杂志,2000,18(2):72-73. 被引量:5
  • 8Nelson HS. Prospects for antihistamines in the treatment of asthma [ J ]. J Allergy Clin Immunol, 2003,112 : 96-100.
  • 9Cigana C, Assael BM, MeIotti P.Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epi- thelial cells [J]. Antimicrob Agents Chemother, 2007, 51: 975-981.
  • 10Beigelman A, Gunsten S, Mikols CL, et ah Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma [ J J. Chest, 2009,136 (2) : 498-506.

二级参考文献12

共引文献2638

同被引文献212

引证文献27

二级引证文献162

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部